H.C. Wainwright lowered the firm’s price target on Arvinas (ARVN) to $81 from $87 and keeps a Buy rating on the shares. Given the company’s ...

H.C. Wainwright lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps a Neutral rating on the shares. The ...

Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Viking Therapeutics in a research note issued on Thursday, February 6th. HC Wainwright analyst J. Pantginis expects that ...

H.C. Wainwright adjusted its price target for Largo Resources Ltd. (NASDAQ:LGO) to $3.70, down from the previous $4.20, while maintaining a "Buy" rating on the stock. The firm's decision follows Largo ...

D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at ...

H.C. Wainwright analyst Scott Buck revised the price target on Yatra Online (NASDAQ:YTRA) to $3.00 from the previous $4.00, while maintaining a Buy rating on the company's stock. The adjustment ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

Management lowered fiscal 2025 revenue guidance to $77M to $83M, reflecting timing changes in large projects. For Q4 2025, revenue is expected to range between $19M and $25M. Jenkins shared confidence ...

Revenue for Q4 2024 was reported at $17.3 million, an 86.8% year-over-year increase and a 21.3% sequential rise. Regional contributions included EMEA at $11.2 million (65% of total revenue), Americas ...